Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.

The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Begent, R. H., Ledermann, J. A., Green, A. J., Bagshawe, K. D., Riggs, S. J., Searle, F., Keep, P. A., Adam, T., Dale, R. G., Glaser, M. G.
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Nature Publishing Group 1989
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2247181/
https://ncbi.nlm.nih.gov/pubmed/2789951
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
id pubmed-2247181
record_format dspace
spelling pubmed-22471812009-09-10 Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Begent, R. H. Ledermann, J. A. Green, A. J. Bagshawe, K. D. Riggs, S. J. Searle, F. Keep, P. A. Adam, T. Dale, R. G. Glaser, M. G. Br J Cancer Research Article The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were found in tumour 8 h after administration and varied up to 9-fold in different patients. Higher levels were found on average in tumour than in any other tissue. Liver, lung and blood were the other tissues in which antibody was concentrated relative to the rest of the body. Antibody cleared from all these tissues over 1 week. Second antibody directed against the antitumour (first) antibody was given 24 h after first antibody in order to accelerate clearance from the blood. This increased the tumour to blood ratio but had little effect on other tissues. Cumulative radiation dose to tumour and normal tissue was estimated. In patients with the most efficient localisation the tumour to body ratio was 20:1 and tumour to blood ratio 5:1. This may be sufficient for effective therapy of cancer in patients selected for efficient antibody localisation. The data may be used to estimate the effect of different therapeutic strategies. For instance, in the time after second antibody administration the average tumour to blood ratio of radiation dose was 11:1, suggesting that two phase systems in which the therapeutic modality is given after a good tumour to normal tissue ratio is obtained may be effective for the majority of patients. IMAGES: Nature Publishing Group 1989-09 /pmc/articles/PMC2247181/ /pubmed/2789951 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
institution US National Library of Medicine
collection PubMed Central
language English
format Article
topic Research Article
spellingShingle Research Article
Begent, R. H.
Ledermann, J. A.
Green, A. J.
Bagshawe, K. D.
Riggs, S. J.
Searle, F.
Keep, P. A.
Adam, T.
Dale, R. G.
Glaser, M. G.
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
description The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were found in tumour 8 h after administration and varied up to 9-fold in different patients. Higher levels were found on average in tumour than in any other tissue. Liver, lung and blood were the other tissues in which antibody was concentrated relative to the rest of the body. Antibody cleared from all these tissues over 1 week. Second antibody directed against the antitumour (first) antibody was given 24 h after first antibody in order to accelerate clearance from the blood. This increased the tumour to blood ratio but had little effect on other tissues. Cumulative radiation dose to tumour and normal tissue was estimated. In patients with the most efficient localisation the tumour to body ratio was 20:1 and tumour to blood ratio 5:1. This may be sufficient for effective therapy of cancer in patients selected for efficient antibody localisation. The data may be used to estimate the effect of different therapeutic strategies. For instance, in the time after second antibody administration the average tumour to blood ratio of radiation dose was 11:1, suggesting that two phase systems in which the therapeutic modality is given after a good tumour to normal tissue ratio is obtained may be effective for the majority of patients. IMAGES:
author Begent, R. H.
Ledermann, J. A.
Green, A. J.
Bagshawe, K. D.
Riggs, S. J.
Searle, F.
Keep, P. A.
Adam, T.
Dale, R. G.
Glaser, M. G.
author_facet Begent, R. H.
Ledermann, J. A.
Green, A. J.
Bagshawe, K. D.
Riggs, S. J.
Searle, F.
Keep, P. A.
Adam, T.
Dale, R. G.
Glaser, M. G.
author_sort Begent, R. H.
title Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
title_short Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
title_full Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
title_fullStr Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
title_full_unstemmed Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
title_sort antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.
publisher Nature Publishing Group
publisher_facet Nature Publishing Group
publishDate 1989
url https://ncbi.nlm.nih.gov/pmc/articles/PMC2247181/
https://ncbi.nlm.nih.gov/pubmed/2789951
_version_ 1760528713269641216

Eitemau Tebyg